Research ArticleArticle
Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis
Fréke Wink, George A. Bruyn, Fiona Maas, Ed N. Griep, Eveline van der Veer, Hendrika Bootsma, Elisabeth Brouwer, Suzanne Arends and Anneke Spoorenberg
The Journal of Rheumatology March 2017, jrheum.160584; DOI: https://doi.org/10.3899/jrheum.160584
Fréke Wink
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
George A. Bruyn
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Fiona Maas
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Ed N. Griep
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Eveline van der Veer
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Hendrika Bootsma
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Elisabeth Brouwer
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Suzanne Arends
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Anneke Spoorenberg
From the Department of Rheumatology and Clinical Immunology, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. The Groningen Leeuwarden AS cohort was supported by an unrestricted grant from Pfizer pharmaceuticals. Pfizer had no role in the design, conduct, interpretation, or publication of this study. F. Wink, MD, Department of Rheumatology, Medical Center Leeuwarden; G.A. Bruyn, MD, Department of Rheumatology, MC Groep; F. Maas, MSc, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E.N. Griep, MD, PhD, Antonius Ziekenhuis Sneek; E. van der Veer, PhD, Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Professor, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, and Department of Rheumatology, Medical Center Leeuwarden; A. Spoorenberg, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Department of Rheumatology, Medical Center Leeuwarden. Address correspondence to Dr. F. Wink, Rheumatology and Clinical Immunology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: f.r.wink@umcg.nl. Accepted for publication December 15, 2016.
Data supplements
Data Supplement
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis
Fréke Wink, George A. Bruyn, Fiona Maas, Ed N. Griep, Eveline van der Veer, Hendrika Bootsma, Elisabeth Brouwer, Suzanne Arends, Anneke Spoorenberg
The Journal of Rheumatology Mar 2017, jrheum.160584; DOI: 10.3899/jrheum.160584
Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis
Fréke Wink, George A. Bruyn, Fiona Maas, Ed N. Griep, Eveline van der Veer, Hendrika Bootsma, Elisabeth Brouwer, Suzanne Arends, Anneke Spoorenberg
The Journal of Rheumatology Mar 2017, jrheum.160584; DOI: 10.3899/jrheum.160584